Meeting NewsVideo

VIDEO: Brolucizumab treatment frequency predicted by first dosing interval

HONOLULU — The recent HAWK and HARRIER trials of Novartis’ brolucizumab for the treatment of neovascular age-related macular degeneration has helped researchers predict which patients will need an 8-week dosing regimen or a 12-week regimen with an almost 90% predictability rate, Pravin Dugel, MD, said at the Association for Research in Vision and Ophthalmology meeting here.

HONOLULU — The recent HAWK and HARRIER trials of Novartis’ brolucizumab for the treatment of neovascular age-related macular degeneration has helped researchers predict which patients will need an 8-week dosing regimen or a 12-week regimen with an almost 90% predictability rate, Pravin Dugel, MD, said at the Association for Research in Vision and Ophthalmology meeting here.

    See more from Association for Research in Vision and Ophthalmology